Featured 13F manager
Opaleye Management Inc. James Silverman
Boston, MA 23 processed 13Fs on this site · 2021 Q3–2026 Q2
- $1.1B
- 58 Positions
- 2026 Q2
- +45.5% QoQ
- Top 5 46.8%
James Silverman files Opaleye Management Inc. as a Form 13F. The latest book is 2026 Q2 at $1.1B, up 45.5% QoQ, led by Liquidia, Eton Pharmaceuticals, and Harrow.
Portfolio
top 5 46.8% · top 10 64.8%
- LQDA - Liquidia 17.7%
- ETON - Eton Pharmaceuticals 9.4%
- HROW - Harrow 9.2%
- IRON - Disc Medicine 5.7%
- URGN - Urogen Pharma 4.8%
- APGE - Apogee Therapeutics 4.7%
- MGTX - Meiragtx 4.3%
- SLGL - Sol-Gel Technologies 3.3%
- RZLT - Rezolute 3.0%
- TGTX - Tg Therapeutics 2.7%
- IMMX - Immix Biopharma 2.2%
- CBIO - Crescent Biopharma 2.1%
- Other 30.9%
AUM over time
Book
| HROW - Harrow Health | 23.43% | Hold | 3,990,000 | $33.55 | $134M | — | — |
| TGTX - Tg Therapeutics | 11.90% | Reduce −0.9% | 2,260,000 | $30.10 | $68M | −20,000 | +$15M |
| CDXS - Codexis | 7.38% | Add +0.8% | 8,840,000 | $4.77 | $42M | +70,000 | +$15M |
| ETON - Eton Pharmaceuticals | 6.65% | Add +2.6% | 2,852,070 | $13.32 | $38M | +72,070 | +$21M |
| OCUL - Ocular Therapeutix | 6.49% | Reduce −13.6% | 4,342,500 | $8.54 | $37M | −682,500 | −$7M |
| ARVN - Arvinas | 5.89% | Add +29.5% | 1,625,000 | $20.70 | $34M | +370,000 | +$3M |
| RYTM - Rhythm Pharmaceuticals | 4.90% | Hold | 500,000 | $55.98 | $28M | — | — |
| Immunome | 3.79% | Add +64.8% | 2,040,000 | $10.62 | $22M | +802,500 | +$4M |
| LQDA - Liquidia | 3.49% | Hold | 1,698,142 | $11.76 | $20M | — | — |
| EWTX - Edgewise Therapeutics | 2.24% | Reduce −8.1% | 480,000 | $26.70 | $13M | −42,500 | −$1M |
| DNA - Ginkgo Bioworks · CLASS A | 2.06% | Add +46.3% | 1,200,000 | $9.82 | $12M | +379,798 | +$5M |
| Cargo Therapeutics | 1.89% | Add +38.5% | 750,000 | $14.42 | $11M | +208,563 | −$1M |
| Protara Therapeutics | 1.69% | Add +8.6% | 1,825,000 | $5.28 | $10M | +143,846 | +$7M |
| TRVI - Trevi Therapeutics | 1.67% | Reduce −9.8% | 2,317,500 | $4.12 | $10M | −250,490 | +$971K |
| Jasper Therapeutics | 1.50% | Add +13.2% | 400,000 | $21.38 | $9M | +46,500 | +$2M |
| NAMS - Newamsterdam Pharma | 1.46% | Reduce −3.0% | 325,000 | $25.70 | $8M | −10,000 | +$3M |
| Acelyrin | 1.26% | Add +18.0% | 2,235,000 | $3.21 | $7M | +341,340 | −$2M |
| NRIX - Nurix Therapeutics | 1.25% | Reduce −9.9% | 378,500 | $18.84 | $7M | −41,500 | −$2M |
| XOMA - XOMA Del | 1.15% | Hold | 250,000 | $26.28 | $7M | — | — |
| PCVX - Vaxcyte | 1.07% | Reduce −11.8% | 75,000 | $81.86 | $6M | −10,000 | −$4M |
| ZNTL - Zentalis Pharmaceuticals | 0.94% | Add +82.8% | 1,767,500 | $3.03 | $5M | +800,500 | +$2M |
| Biodesix | 0.93% | Reduce −9.2% | 3,465,000 | $1.53 | $5M | −350,000 | −$2M |
| NUVL - Nuvalent | 0.80% | Reduce −8.6% | 58,500 | $78.28 | $5M | −5,500 | −$2M |
| Gossamer Bio | 0.71% | Add +22.5% | 4,490,000 | $0.9046 | $4M | +824,990 | +$356K |
| PTGX - Protagonist Therapeutics | 0.71% | Hold | 105,000 | $38.60 | $4M | — | — |
| Essa Pharma | 0.69% | New | 2,209,998 | $1.79 | $4M | +2,209,998 | +$4M |
| ABCL - Abcellera Biologics | 0.49% | Add +20.6% | 965,000 | $2.93 | $3M | +165,000 | +$747K |
| URGN - Urogen Pharma | 0.41% | Reduce −45.6% | 220,000 | $10.65 | $2M | −184,100 | −$3M |
| RZLT - Rezolute | 0.40% | Reduce −0.3% | 465,000 | $4.90 | $2M | −1,563 | +$16K |
| Immatics | 0.21% | New | 165,000 | $7.11 | $1M | +165,000 | +$1M |
| IBIO — | 0.16% | Hold | 375,000 | $2.45 | $919K | — | — |
| LXEO - Lexeo Therapeutics | 0.15% | New | 130,000 | $6.58 | $855K | +130,000 | +$855K |
| REGENXBIO | 0.11% | New | 80,000 | $7.73 | $618K | +80,000 | +$618K |
| Ventyx Biosciences | 0.11% | New | 280,000 | $2.19 | $613K | +280,000 | +$613K |
| PEPG - Pepgen | 0.07% | Reduce −38.6% | 110,000 | $3.79 | $417K | −69,200 | −$1M |
| STOK - Stoke Therapeutics | 0.05% | New | 25,000 | $11.03 | $276K | +25,000 | +$276K |
| ADGM - Adagio Med | 0.02% | Hold | 110,571 | $1.05 | $116K | — | — |
Exits / last held
not current holdings · last reported size, unchanged · gone vs 2024 Q3
| Stock | % of portfolio | Recent activity | Shares | Reported price* | Value | Share change | $ change |
|---|---|---|---|---|---|---|---|
| Keros Therapeutics | 3.83% | Exit | 0 | $58.07 | $23M | −395,276 | −$23M |
| APLT - Applied Therapeutics ' | 1.87% | Exit | 0 | $8.50 | $11M | −1,320,000 | −$11M |
| CYTK - Cytokinetics | 0.66% | Exit | 0 | $52.80 | $4M | −75,300 | −$4M |
| Catalyst Pharmaceuticals | 0.37% | Exit | 0 | $19.88 | $2M | −112,500 | −$2M |
| Lyell Immunopharma | 0.32% | Exit | 0 | $1.38 | $2M | −1,395,000 | −$2M |
| Allakos | 0.26% | Exit | 0 | $0.6533 | $2M | −2,407,600 | −$2M |
| RLMD - Relmada Therapeutics | 0.26% | Exit | 0 | $3.24 | $2M | −480,000 | −$2M |
| Revance Therapeutics | 0.24% | Exit | 0 | $5.19 | $1M | −275,000 | −$1M |
| Syros Pharmaceuticals | 0.23% | Exit | 0 | $2.15 | $1M | −654,943 | −$1M |
| Aerovate Therapeutics | 0.15% | Exit | 0 | $2.09 | $920K | −440,000 | −$920K |
| Regulus Therapeutics | 0.14% | Exit | 0 | $1.57 | $840K | −535,000 | −$840K |
Filings history
20 periods · normalized AUM · open a period for holdings
| Period | Holdings | AUM | QoQ | Form | Filed | Filing ID |
|---|---|---|---|---|---|---|
| 2026 Q2 | 58 | $1.1B | +45.5% | 13F-HR | 8/14/2026 | 000142050626001803 |
| 2026 Q1 | 54 | $759M | +0.1% | 13F-HR | 5/15/2026 | 000142050626001151 |
| 2025 Q4 | 54 | $758M | — | RESTATEMENT | 4/13/2026 | 000149315226016299 |
| 2025 Q4 | 54 | $758M | +7.2% | 13F-HR | 2/17/2026 | 000149315226007085 |
| 2025 Q3 | 43 | $707M | +41.7% | 13F-HR | 11/14/2025 | 000149315225023429 |
| 2025 Q2 | 41 | $494M | — | RESTATEMENT | 8/15/2025 | 000164117225024301 |
| 2025 Q2 | 41 | $499M | +11.1% | 13F-HR | 8/14/2025 | 000164117225023977 |
| 2025 Q1 | 45 | $449M | −21.4% | 13F-HR | 5/15/2025 | 000164117225010914 |
| 2024 Q4 | 39 | $571M | −4.8% | 13F-HR | 2/14/2025 | 000149315225006852 |
| 2024 Q3 | 44 | $600M | +37.0% | 13F-HR | 11/14/2024 | 000149315224045811 |
| 2024 Q2 | 51 | $438M | +0.2% | 13F-HR | 8/14/2024 | 000149315224032150 |
| 2024 Q1 | 52 | $459M | — | RESTATEMENT | 5/29/2024 | 000149315224021780 |
| 2024 Q1 | 51 | $437M | +16.2% | 13F-HR | 5/15/2024 | 000149315224019869 |
| 2023 Q4 | 47 | $376M | +22.5% | 13F-HR | 2/14/2024 | 000149315224006653 |
| 2023 Q3 | 41 | $307M | −26.6% | 13F-HR | 11/15/2023 | 000149315223041364 |
| 2023 Q2 | 47 | $418M | +25.1% | 13F-HR | 8/14/2023 | 000149315223028636 |
| 2023 Q1 | 41 | $334M | +16.0% | 13F-HR | 5/15/2023 | 000149315223016769 |
| 2022 Q4 | 40 | $288M | +19.0% | 13F-HR | 2/10/2023 | 000149315223004277 |
| 2022 Q3 | 42 | $242M | +9.0% | 13F-HR | 11/14/2022 | 000149315222032068 |
| 2022 Q2 | 47 | $222M | −31.1% | 13F-HR | 8/15/2022 | 000149315222022856 |
| 2022 Q1 | 45 | $322M | −31.6% | 13F-HR | 5/16/2022 | 000149315222013764 |
| 2021 Q4 | 39 | $471M | −12.0% | 13F-HR | 2/14/2022 | 000149315222004434 |
| 2021 Q3 | 48 | $535M | — | 13F-HR | 11/16/2021 | 000149315221028799 |
About
Opaleye Management Inc.
23 processed 13Fs on this site · 2021 Q3–2026 Q2